

Periods	Baseline	L-NMMA		Post infusion		p (GLM-within)
	Prior to L-NMMA infusion	At the beginning of infusion	At the end of infusion	30 min after the end of L-NMMA infusion	60 min after the end of L-NMMA infusion	
<b>SBP (mmHG)</b>						
Placebo	113± 8	116± 8	116± 8	117± 9	118±10	0.179
Tolvaptan 15 mg	114± 8	118±8	117± 7	115± 6	117± 7	
Tolvaptan 30 mg	114± 9	116± 8	116± 8	117± 9	118± 9	
Tolvaptan 45 mg	114± 10	116± 7	117± 9	117± 8*	119± 10	
p (GLM between)			0.993			
<b>DBP (mmHg)</b>						
Placebo	62± 5	68± 7*	68± 5	67± 6	66± 7	0.691
Tolvaptan 15 mg	62± 7	68± 7	67± 8	65± 6	66± 7	
Tolvaptan 30 mg	62± 6	68± 6	68± 7	67± 6	66± 6	
Tolvaptan 45 mg	61± 6	68± 6	68± 7	66± 8	67± 8	
p (GLM between)			0.997			
<b>Pulse rate (BPM)</b>						
Placebo	57±9	52±10	53 ±8	56± 9	59 ±10	0.149
Tolvaptan 15 mg	58± 9	51±8	51±8	55±7	58±8	
Tolvaptan 30 mg	58±8	54±8	54±8	57±8	61±9	
Tolvaptan 45 mg	57± 8	53± 7	53 ± 8	55 ±8	59± 9	
p (GLM between)			0.906			